Market revenue in 2023 | USD 677.4 million |
Market revenue in 2030 | USD 1,382.1 million |
Growth rate | 10.7% (CAGR from 2023 to 2030) |
Largest segment | Surgery |
Fastest growing segment | Intralesional injections |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Radiotherapy (RT), Intralesional injections, Intravenous Medications, Chemical peeling treatment, Surgery, Topical chemotherapy, Oral Medications |
Key market players worldwide | Bausch Health Companies Inc, Almirall SA, Genentech, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Dr Reddy's Laboratories Ltd ADR, Taro Pharmaceuticals, Accord Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to basal cell carcinoma treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 35.87% in 2023. Horizon Databook has segmented the Europe basal cell carcinoma treatment market based on radiotherapy (rt), intralesional injections, intravenous medications, chemical peeling treatment, surgery, topical chemotherapy, oral medications covering the revenue growth of each sub-segment from 2018 to 2030.
According to the International Agency for Research on Cancer, in 2022, NMSC prevalence cases reported in Europe were 303,693. In addition, the aging population in Europe is mainly susceptible to BCC due to cumulative sun exposure over the years.
As the proportion of older adults increases, the demand for BCC treatments is also expected to rise. Innovations in treatment technologies, including advanced surgical techniques, radiation therapy, and novel topical and systemic medications, drive the market.
The development of targeted therapies and less invasive treatment options has improved outcomes and patient preference for these newer treatments. European countries with well-established healthcare systems and broad access to healthcare services.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe basal cell carcinoma treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe basal cell carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account